Assetmark Inc. Acquires 908 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Assetmark Inc. increased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,442 shares of the specialty pharmaceutical company’s stock after purchasing an additional 908 shares during the period. Assetmark Inc. owned approximately 0.06% of Supernus Pharmaceuticals worth $1,043,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Sei Investments Co. boosted its holdings in shares of Supernus Pharmaceuticals by 24.4% in the first quarter. Sei Investments Co. now owns 330,580 shares of the specialty pharmaceutical company’s stock valued at $11,276,000 after buying an additional 64,752 shares during the period. Russell Investments Group Ltd. lifted its position in Supernus Pharmaceuticals by 205.2% in the 1st quarter. Russell Investments Group Ltd. now owns 97,988 shares of the specialty pharmaceutical company’s stock valued at $3,342,000 after acquiring an additional 65,880 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in Supernus Pharmaceuticals by 250.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 49,160 shares of the specialty pharmaceutical company’s stock worth $1,781,000 after purchasing an additional 35,137 shares during the period. Renaissance Technologies LLC increased its holdings in Supernus Pharmaceuticals by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock worth $45,077,000 after purchasing an additional 351,900 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in shares of Supernus Pharmaceuticals by 1,508.0% in the 2nd quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock valued at $3,287,000 after purchasing an additional 109,088 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SUPN. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 125,000 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the transaction, the chief executive officer now owns 926,172 shares of the company’s stock, valued at $33,971,988.96. The trade was a 11.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Georges Gemayel sold 14,213 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the completion of the sale, the director now directly owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. The trade was a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 154,213 shares of company stock valued at $5,660,180. 9.30% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $36.18 on Friday. The company has a market cap of $2.00 billion, a price-to-earnings ratio of 33.81 and a beta of 0.86. The firm has a 50-day moving average of $33.32 and a 200-day moving average of $30.88. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The firm had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. During the same period in the prior year, the firm posted ($0.29) earnings per share. The business’s quarterly revenue was up 14.2% compared to the same quarter last year. As a group, sell-side analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.